Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
Fred Hutchinson Cancer Center
University of Nebraska
Boston Children's Hospital
Dana-Farber Cancer Institute
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
Rush University Medical Center
University of California, San Diego
University of Southampton
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Therapeutic Advances in Childhood Leukemia Consortium
University of California, San Francisco
University of California, San Francisco
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Tufts Medical Center
Wake Forest University Health Sciences
Children's Mercy Hospital Kansas City
St. Jude Children's Research Hospital
Therapeutic Advances in Childhood Leukemia Consortium
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lymphoma Study Association
M.D. Anderson Cancer Center
Sun Yat-sen University
Masonic Cancer Center, University of Minnesota
Stanford University
UNC Lineberger Comprehensive Cancer Center
Fondazione Italiana Linfomi - ETS
French Innovative Leukemia Organisation
French Innovative Leukemia Organisation
Stanford University
New Mexico Cancer Research Alliance
Dartmouth-Hitchcock Medical Center
M.D. Anderson Cancer Center
Stanford University
H. Lee Moffitt Cancer Center and Research Institute
Medical College of Wisconsin
Dana-Farber Cancer Institute
St. Jude Children's Research Hospital
Gustave Roussy, Cancer Campus, Grand Paris